MX2022008060A - Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. - Google Patents

Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.

Info

Publication number
MX2022008060A
MX2022008060A MX2022008060A MX2022008060A MX2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A
Authority
MX
Mexico
Prior art keywords
variant
hyaluronic acid
pharmaceutical composition
same
improved stability
Prior art date
Application number
MX2022008060A
Other languages
English (en)
Inventor
Soon Jae Park
Hyung- Nam Song
Hye- Shin CHUNG
Seung Joo Lee
Kyuwan Kim
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of MX2022008060A publication Critical patent/MX2022008060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se divulgan nuevas variantes de PH20 o fragmentos de las mismas con estabilidad térmica y actividad enzimática mejoradas de la hialuronidasa humana, que es una enzima que hidroliza el ácido hialurónico, y más particularmente nuevas variantes de PH20 o fragmentos de las mismas que incluyen una o más sustituciones de residuos de aminoácidos en la variante que tiene la secuencia de aminoácidos de SEQ ID NO: 3, en la que uno o más residuos de aminoácidos en el N-terminal y/o en el C-terminal se eliminan opcionalmente.
MX2022008060A 2020-01-23 2021-01-25 Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. MX2022008060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200009046 2020-01-23
PCT/KR2021/000943 WO2021150079A1 (ko) 2020-01-23 2021-01-25 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2022008060A true MX2022008060A (es) 2022-07-27

Family

ID=76992900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008060A MX2022008060A (es) 2020-01-23 2021-01-25 Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.

Country Status (12)

Country Link
US (1) US20230250408A1 (es)
EP (1) EP3992285A4 (es)
JP (2) JP2022552756A (es)
KR (2) KR20250065714A (es)
CN (3) CN113840921A (es)
AU (2) AU2021211348B2 (es)
BR (1) BR112021022739A2 (es)
CA (1) CA3137324A1 (es)
MX (1) MX2022008060A (es)
TW (1) TW202302845A (es)
WO (1) WO2021150079A1 (es)
ZA (1) ZA202206370B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021616A (ko) 2018-07-25 2025-02-13 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
CA3173310A1 (en) 2020-08-07 2022-02-10 Alteogen, Inc. Method for producing recombinant hyaluronidase
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
PL4267105T3 (pl) 2020-12-28 2025-06-30 Bristol-Myers Squibb Company Kompozycje przeciwciał i metody ich stosowania
CA3232451A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
CN119562830A (zh) 2022-06-02 2025-03-04 百时美施贵宝公司 抗体组合物及其使用方法
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
US20250122492A1 (en) * 2022-06-22 2025-04-17 Alteogen, Inc. N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
US20250345403A1 (en) * 2022-06-29 2025-11-13 Odysgen Inc. Hyaluronidase hyal1 variant exhibiting activity in neutral ph
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
CN120936341A (zh) 2022-12-22 2025-11-11 海洋酶公司 用于高体积施用的透明质酸酶制剂
CN120936711A (zh) * 2023-03-23 2025-11-11 阿特根公司 新型透明质酸酶变体及包括其的药物组合物
KR102875495B1 (ko) * 2023-12-28 2025-10-27 주식회사 오디스젠 히알루로니다제 Hyal1 변이체
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187427A1 (en) * 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
DK3037529T3 (da) * 2008-12-09 2019-05-20 Halozyme Inc Udvidede opløselige ph20-polypeptider og anvendelse deraf
WO2012174478A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
HUE047849T2 (hu) * 2011-12-30 2020-05-28 Halozyme Inc PH20 polipeptid variánsok, készítmények, és azok alkalmazása
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
KR20250021616A (ko) * 2018-07-25 2025-02-13 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
PE20220283A1 (es) * 2019-03-25 2022-02-25 Alteogen Inc Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento

Also Published As

Publication number Publication date
TW202302845A (zh) 2023-01-16
AU2021211348A1 (en) 2021-12-09
AU2021211348B2 (en) 2023-10-05
CN120699939A (zh) 2025-09-26
JP2022552756A (ja) 2022-12-20
ZA202206370B (en) 2023-06-28
KR20220069045A (ko) 2022-05-26
TW202140780A (zh) 2021-11-01
CA3137324A1 (en) 2021-07-29
EP3992285A4 (en) 2023-01-25
KR102801434B1 (ko) 2025-04-30
AU2024200091A1 (en) 2024-01-25
KR20250065714A (ko) 2025-05-13
US20230250408A1 (en) 2023-08-10
JP2024095673A (ja) 2024-07-10
BR112021022739A2 (pt) 2022-08-09
WO2021150079A1 (ko) 2021-07-29
CN113840921A (zh) 2021-12-24
CN120966799A (zh) 2025-11-18
EP3992285A1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
MX2022008060A (es) Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
MY204342A (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
NZ597306A (en) Mesenchymal stem cell differentiation
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
JP7699196B2 (ja) ブタトリプシンの変異体
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ZA202404727B (en) N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof
MX2025009545A (es) Metodos y composiciones para la administracion de sistemas de vector dual otoferlin
JP2020037538A5 (es)
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
Brunati et al. Isolation and identification of two proto‐oncogene products related to c‐fgr and fyn in a tyrosine‐protein‐kinase fraction of rat spleen
WO2019219903A3 (en) Mutant lipase and use thereof
KR102565312B1 (ko) 활성화된 클로스트리디움 신경독소의 생산
MX2020014191A (es) Variantes de enzimas lipoliticas.
MX2020010422A (es) Alfa-amilasa maltogenica variante.
WO2023102407A3 (en) Engineered high activity omni-79 nuclease variants
WO2025077943A3 (zh) TST3b蛋白质及其相关生物材料在调控番茄可溶性糖含量中的应用
WO2023144753A3 (en) Recombinant expression of fumonisin esterase, compositions and uses thereof
MX2025009803A (es) PROTEÍNA DE FUSIÓN QUE COMPRENDE FRAGMENTO DE LA REGIÓN EXTRACELULAR DE TGF-ßRII, COMPOSICIÓN FARMACÉUTICA DE LA MISMA Y USO DE LA MISMA
WO2021207706A3 (en) Methods and compositions for inactivating interleukin-2-inducible t-cell kinase (itk)
JP2018143142A5 (es)
MY182816A (en) Cancer antigen peptide